|
Session 173-Poster Abstracts
ART Pharmacokinetics, Safety, and Efficacy in Children
Wednesday, 2-4 pm; Poster Hall |
872
 |
A Pharmacokinetic Comparison of Adult and Pediatric Formulations of RAL in Healthy Adults
Diana Brainard*1, N Gendrano III1, B Jin1, S Breidinger1, W Lewis2, L Wenning1, J Wagner1, and M Iwamoto1
1Merck & Co, Rahway, NJ, US and 2Covance Clin Res Unit, Austin, TX, US |
873
|
Pharmacokinetic, Safety, and Efficacy Data on Cohort IIA; Youth Aged 6 to 11 Years from IMPAACT P1066: A Phase I/II Study to Evaluate Raltegravir in HIV-1-infected Youth
Sharon Nachman*1, P Samson2, E Acosta3, H Teppler4, C Welebob4, T Fenton2, E Handelsman5, C Worrell6, B Graham7, A Wiznia8, and the P1066 Group
1State Univ of New York at Stony Brook, US; 2Ctr for Biostatistics in AIDS Res, Harvard Sch of Publ Hlth, Boston, MA, US; 3Univ of Alabama at Birmingham, US; 4Merck Res Labs, North Wales, PA, US; 5Div of AIDS, NIH, Bethesda, MD, US; 6Natl Inst of Child Hlth and Human Devt, NIH, Bethesda, MD, US; 7Frontier Sci and Tech Res Fndn, Buffalo, NY, US; and 8Jacobi Med Ctr, Bronx, NY, US |
874
|
Pharmacokinetics and Safety of Once-daily Elvitegravir in HIV-infected Adolescents
Aditya Gaur*1, J Abadi2, A Wiznia2, W Borkowsky3, G Tudor-Williams4, C Cunningham5, S Ramanathan6, H Liu6, and S Chuck6
1St Jude Children’s Res Hosp, Memphis, TN, US; 2Jacobi Med Ctr, Bronx, NY, US; 3New York Univ Sch of Med, NY, US; 4Imperial Coll London, UK; 5Duke Univ Med Ctr, Durham, NC, US; and 6Gilead Sci, Foster City, CA, US |
| 875 |
A Pharmacokinetic Study of Ritonavir-boosted Saquinavir in HIV-infected Children 4 Months to <6 Years Old
Joshua Haznedar*1, A Zhang2, E Labriola-Tompkins2, G Ezcurra3, T Bunupuradah4, P Kosalaraksa5, T Chotpitayasunondh6, M Salgo2, L Donatacci2, and I Patel2
1Roche, Palo Alto, CA, US; 2Roche, Nutley, NJ, US; 3Hosp de Niños Dr Orlando Alassia, Santa Fe, Argentina; 4HIVNAT Res Collaboration, Thai Red Cross AIDS Res Ctr, Bangkok; 5Srinagarind Hosp, Khon Kaen, Thailand; and 6Queen Sirikit Natl Inst of Child Hlth, Bangkok, Thailand |
876
|
Long-term (>180 Weeks) Efficacy and Safety of Fosamprenavir in HIV-infected Pediatric Patients in Clinical Practice
C Palladino1, Verónica Briz*1, S Negre-Policarpo2, M I de José3, M I González-Tomé4, D Moreno Pérez5, J Leon Leal6, M J Mellado7, J Ramos8, and M Á Muñoz-Fernández1
1Hosp Gen Univ Gregorio Marañón, Madrid, Spain; 2Hosp Univ La Fe, Valencia, Spain; 3Hosp Univ La Paz, Madrid, Spain; 4Hosp Univ 12 de Octubre, Madrid, Spain; 5Hosp Regional Univ Carlos Haya, Malaga, Spain; 6Hosp Infantil Univ Virgen del Rocio, Sevilla, Spain; 7Hosp Carlos III, Madrid, Spain; and 8Hosp Univ de Getafe, Madrid, Spain |
877
|
Pharmacokinetics of Lopinavir/Ritonavir Crushed vs Whole Tablets in Children
H Diep1, Brookie Best*1, E Capparelli1, S Rossi1, M Farrell1, E Williams2, G Lee2, J van den Anker2, and N Rakhmanina2
1Univ of California, San Diego, US and 2Children’s Natl Med Ctr, Washington, DC, US |
878
|
Pharmacokinetics of Efavirenz Dosed according to the WHO Weight-bands in Children in Uganda
S Bakeera-Kitaka1, E Natukunda2, L Kendall3, Quirine Fillekes*4, A Kekitiinwa1, C Tumusiime2, P Mugyenyi2, A S Walker3, D Gibb3, D Burger4, and the ARROW Trial Team
1Pediatric Infectious Diseases Ctr, Mulago, Uganda; 2Joint Clin Res Ctr, Kampala, Uganda; 3Med Res Council Clin Trials Unit, London, UK; and 4Radboud Univ Nijmegen Med Ctr, The Netherlands |
879
|
Safety and Efficacy of NRTI-only Antiretroviral Regimens in HIV-infected Children
Michael Neely*1, R Rutstein2, G del Bianco3, G Heresi3, T Barton4, J Wheeling5, R Wiegand6, B Bohannon6, K Dominguez6, A Wiznia7, and the LEGACY Consortium
1Univ of Southern California, Keck Sch of Med, Los Angeles, US; 2Children’s Hosp of Philadelphia, PA, US; 3Univ of Texas Hlth Sci Ctr at Houston, US; 4Univ of Texas Southwestern Med Ctr, Dallas, US; 5Northrup Grummon, Inc, Atlanta, GA, US; 6CDC, Atlanta, GA, US; and 7Jacobi Med Ctr, Bronx, NY, US |
|
